Pharma

Your Article Summary

See Latest Articles

Randomized phase 2 study of imc-a12 for her2-expressing advanced breast cancer commences patient enrollment
ImClone Sytems, 11/20/08

ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Erlotinib Warning
JAMA, 06/29/09

Astellas Names Head of Global R and D Operations
Astellas, 06/11/09

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
Expert Opinion in Pharmacotherapy, 06/19/09

See All of Research & Development